{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T09:08:41Z","timestamp":1789117721555,"version":"build-2803163510"},"reference-count":58,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100017638","name":"Ministry of Health of the Russian Federation government contract","doi-asserted-by":"publisher","award":["125020401358-1"],"award-info":[{"award-number":["125020401358-1"]}],"id":[{"id":"10.13039\/501100017638","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background\/Objectives: The impact of repeated annual influenza vaccination on long-term immunogenicity and protection remains debated. Although reduced fold-increases in antibody titers are often observed in repeatedly vaccinated individuals, the effect on the duration of the humoral response remains poorly understood. This study evaluated the magnitude and persistence of the humoral immune response over four consecutive seasons. Methods: An open-label observational study was conducted between 2018 and 2022 and involved 28 healthy adults (median age, 55 years) immunized with seasonal inactivated influenza vaccines. Hemagglutination inhibition (HAI) titers were assessed at five time points annually. Secondary endpoints included neutralizing (MNA) and neuraminidase-inhibiting (ELLA) antibody responses measured at baseline and three weeks after vaccination. The duration of antibody responses above the seroprotection threshold (titer \u2265 40) was compared across seasons using the Mantel\u2013Cox test. Results: Antibody dynamics differed by vaccine component. The highest GMT and fold-increase were observed for A\/H1N1pdm09 in 2018\/19, followed by a significant decline after the second vaccination, that was more pronounced for neutralizing antibodies. The response to N1 neuraminidase remained weak throughout the study. For A\/H3N2, baseline HAI GMTs increased significantly after each subsequent vaccination, whereas N2 neuraminidase responses peaked after the first dose and declined thereafter. Influenza B responses were weaker than those to influenza A. A significant increase in B\/Yamagata titers in 2020\/21 was attributed to the introduction of quadrivalent vaccines. A\/H1N1pdm09 HAI responses were long-lasting, with titers remaining at or above the seroprotection threshold for one year. The duration of the A\/H3N2 antibody response increased significantly over four seasons, likely because of annual strain updates. A similar trend was observed for B\/Victoria after strain changes. Conclusions: Repeated annual influenza vaccination did not negatively affect post-vaccination antibody titers to the HA vaccine antigens in the studied cohort. Regular updates to vaccine strains may enhance the persistence of HA-targeted humoral immune responses.<\/jats:p>","DOI":"10.3390\/vaccines14090800","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:17:42Z","timestamp":1789114662000},"page":"800","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Duration of the Humoral Immune Response to Influenza Vaccination in a Cohort of Repeatedly Vaccinated Adults over Four Consecutive Epidemic Seasons: 2018\/19\u20132021\/22 Observational Study"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0411-9896","authenticated-orcid":false,"given":"Mariia V.","family":"Sergeeva","sequence":"first","affiliation":[{"name":"Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, Saint Petersburg 197022, Russia"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"conceptualization","vocabulary":"credit"},{"role":"software","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"writing-review-editing","vocabulary":"credit"},{"role":"visualization","vocabulary":"credit"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3342-5828","authenticated-orcid":false,"given":"Polina","family":"Kudar","sequence":"additional","affiliation":[{"name":"FSBSI \u2018Institute of Experimental Medicine\u2019, Saint Petersburg 197022, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9794-3520","authenticated-orcid":false,"given":"Yulia","family":"Desheva","sequence":"additional","affiliation":[{"name":"FSBSI \u2018Institute of Experimental Medicine\u2019, Saint Petersburg 197022, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7560-398X","authenticated-orcid":false,"given":"Ekaterina","family":"Romanovskaya-Romanko","sequence":"additional","affiliation":[{"name":"Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, Saint Petersburg 197022, Russia"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"validation","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"}]},{"given":"Vera","family":"Krivitskaya","sequence":"additional","affiliation":[{"name":"Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, Saint Petersburg 197022, Russia"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"methodology","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"}]},{"given":"Janna","family":"Buzitskaya","sequence":"additional","affiliation":[{"name":"Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, Saint Petersburg 197022, Russia"}],"role":[{"vocabulary":"crossref","role":"author"},{"role":"formal-analysis","vocabulary":"credit"},{"role":"investigation","vocabulary":"credit"},{"role":"data-curation","vocabulary":"credit"},{"role":"supervision","vocabulary":"credit"}]},{"given":"Marina A.","family":"Stukova","sequence":"additional","affiliation":[{"name":"Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, Saint Petersburg 197022, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3892-9873","authenticated-orcid":false,"given":"Irina","family":"Kiseleva","sequence":"additional","affiliation":[{"name":"FSBSI \u2018Institute of Experimental Medicine\u2019, Saint Petersburg 197022, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3643-7354","authenticated-orcid":false,"given":"Dmitry","family":"Lioznov","sequence":"additional","affiliation":[{"name":"Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, Saint Petersburg 197022, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2022). Vaccines against influenza: WHO position paper\u2013May 2022\u2013Vaccins antigrippaux: Note de synth\u00e8se de l\u2019OMS\u2013mai 2022. Wkly. Epidemiol. Rec., 97, 185\u2013208."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1093\/cid\/ciu680","article-title":"Impact of repeated vaccination on vaccine effectiveness against influenza A(H3N2) and B during 8 seasons","volume":"59","author":"McLean","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1900245","DOI":"10.2807\/1560-7917.ES.2020.25.1.1900245","article-title":"The impact of repeated vaccination using 10-year vaccination history on protection against influenza in older adults: A test-negative design study across the 2010\/11 to 2015\/16 influenza seasons in Ontario, Canada","volume":"25","author":"Kwong","year":"2020","journal-title":"Eurosurveillance"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S2213-2600(22)00266-1","article-title":"Does repeated influenza vaccination attenuate effectiveness? A systematic review and meta-analysis","volume":"11","author":"Robinson","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41541-024-01057-x","article-title":"Antibody responses against influenza A decline with successive years of annual influenza vaccination","volume":"10","author":"Sullivan","year":"2025","journal-title":"npj Vaccines"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Berber, E., Hanley, H.B., Gamez, B.M., and Ross, T.M. (2026). Assessment of hemagglutinin-inhibition activity following influenza vaccination during the 2022\u20132023, 2023\u20132024, and 2024\u20132025 seasons. PLoS ONE, 21.","DOI":"10.1371\/journal.pone.0347314"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1038\/s41467-019-11296-5","article-title":"Repeat vaccination reduces antibody affinity maturation across different influenza vaccine platforms in humans","volume":"10","author":"Khurana","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"335","DOI":"10.4049\/jimmunol.1801149","article-title":"Original antigenic sin: How first exposure shapes lifelong anti-influenza virus immune responses","volume":"202","author":"Zhang","year":"2019","journal-title":"J. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e20241283","DOI":"10.1084\/jem.20241283","article-title":"Vaccination against influenza viruses annually: Renewing or narrowing the protective shield?","volume":"222","author":"Matz","year":"2025","journal-title":"J. Exp. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e13060","DOI":"10.1111\/irv.13060","article-title":"Repeated influenza vaccination induces similar immune protection as first-time vaccination but with differing immune responses","volume":"17","author":"Ye","year":"2023","journal-title":"Influenza Other Respir. Viruses"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41541-019-0123-7","article-title":"Repeated vaccination against matched H3N2 influenza virus gives less protection than single vaccination in ferrets","volume":"4","author":"Music","year":"2019","journal-title":"npj Vaccines"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1093\/infdis\/jiv195","article-title":"Antibody to influenza virus neuraminidase: An independent correlate of protection","volume":"212","author":"Monto","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1093\/infdis\/jis935","article-title":"Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase","volume":"207","author":"Couch","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1080\/14760584.2024.2343689","article-title":"Anti-neuraminidase immunity in the combat against influenza","volume":"23","author":"Zhang","year":"2024","journal-title":"Expert Rev. Vaccines"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e70192","DOI":"10.1111\/irv.70192","article-title":"Human immune response to influenza neuraminidase after vaccination: A systematic review","volume":"19","author":"Ganesh","year":"2025","journal-title":"Influenza Other Respir. Viruses"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Youhanna, J., Puig-Barber\u00e0, J., Miller, M.S., Molrine, D., Hadi, M., Bapat, S., Iheanacho, I., Dodman, S., Fikre, T., and Swinburn, P. (2025). Expert consensus on the benefits of neuraminidase in conventional influenza vaccines: A Delphi study. BMC Infect. Dis., 25.","DOI":"10.1186\/s12879-024-10277-4"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"101136","DOI":"10.1016\/j.lanmic.2025.101136","article-title":"Duration of the serological response and effectiveness of the inactivated influenza vaccine in healthy adults aged 18\u201365 years: A systematic review and meta-analysis","volume":"6","author":"Nazareth","year":"2025","journal-title":"Lancet Microbe"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"e633","DOI":"10.1093\/cid\/ciaa340","article-title":"Waning of measured influenza vaccine effectiveness over time: The potential contribution of leaky vaccine effect","volume":"71","author":"Tokars","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41541-025-01259-x","article-title":"Effects of repeated influenza vaccination and infection on durable seroprotection in healthcare workers","volume":"10","author":"Trieu","year":"2025","journal-title":"npj Vaccines"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/infdis\/jiaa293","article-title":"Influenza A(H1N1)pdm09 but not A(H3N2) virus infection induces durable seroprotection: Results from the Ha Nam cohort","volume":"226","author":"Hoa","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Carregaro, R.L., Roscani, A.N., Raimundo, A.C.S., Ferreira, L., Vanni, T., da Gra\u00e7a Salom\u00e3o, M., Probst, L.F., and Viscondi, J.Y.K. (2023). Immunogenicity and safety of inactivated quadrivalent influenza vaccine compared with the trivalent vaccine for influenza infection: An overview of systematic reviews. BMC Infect. Dis., 23.","DOI":"10.1186\/s12879-023-08541-0"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1093\/infdis\/jiv313","article-title":"Persistence of antibodies to influenza hemagglutinin and neuraminidase following one or two years of influenza vaccination","volume":"212","author":"Petrie","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"127677","DOI":"10.1016\/j.vaccine.2025.127677","article-title":"High-resolution antibody dynamics following influenza vaccination reveal predominantly weak responses as well as infrequent but durable immunity across the 2014\u20132022 seasons","volume":"64","author":"Lane","year":"2025","journal-title":"Vaccine"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"127904","DOI":"10.1016\/j.vaccine.2025.127904","article-title":"Assessing factors associated with one-year antibody waning in participants with repeated influenza vaccinations: A six-year cohort study","volume":"68","author":"Cheng","year":"2025","journal-title":"Vaccine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12979-023-00362-8","article-title":"Interseason waning of vaccine-induced hemagglutination inhibition antibody titers and contributing factors to pre-existing humoral immunity against influenza in community-dwelling older adults 75 years and older","volume":"20","author":"Wunderlich","year":"2023","journal-title":"Immun. Ageing"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Sergeeva, M.V., Romanovskaya-Romanko, E.A., Krivitskaya, V.Z., Kudar, P.A., Petkova, N.N., Kudria, K.S., Lioznov, D.A., Stukova, M.A., and Desheva, Y.A. (2023). Longitudinal analysis of neuraminidase and hemagglutinin antibodies to influenza A viruses after immunization with seasonal inactivated influenza vaccines. Vaccines, 11.","DOI":"10.20944\/preprints202309.1919.v1"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Desheva, Y., Kudar, P., Sergeeva, M., Wong, P.-F., Shvedova, T., Bazhenova, E., Krylova, E., Kurpiaeva, M., Romanovskaya-Romanko, E., and Krivitskaya, V. (2025). The persistence of cross-reactive immunity to influenza B\/Yamagata neuraminidase despite the disappearance of the lineage: Structural and serological evidence. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26157476"},{"key":"ref_28","unstructured":"Committee for Proprietary Medicinal Products (CPMP) (1997). Note for Guidance on Harmonisation of Requirements for Influenza Vaccines, European Agency for the Evaluation of Medicinal Products. CPMP\/BWP\/214\/96."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S2213-2600(21)00511-7","article-title":"Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: A systematic review and modelling analysis","volume":"10","author":"Adeloye","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"ref_30","unstructured":"(2022). The Global Asthma Report. Int. J. Tuberc. Lung Dis., 26, S1\u2013S102."},{"key":"ref_31","unstructured":"NCD Risk Factor Collaboration (NCD-RisC) (2021). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: A pooled analysis of 1201 population-representative studies with 104 million participants. Lancet, 398, 957\u2013980."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"28","DOI":"10.31631\/2073-3046-2021-20-4-28-39","article-title":"Interference of SARS-CoV-2 with other respiratory viral infection agents during the pandemic","volume":"20","author":"Sominina","year":"2021","journal-title":"Epidemiol. Vaccinal Prev."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Sominina, A., Danilenko, D., Komissarov, A., Karpova, L., Pisareva, M., Fadeev, A., Konovalova, N., Eropkin, M., Stolyarov, K., and Shtro, A. (2022). Resurgence of influenza circulation in the Russian Federation during the Delta and Omicron COVID-19 era. Viruses, 14.","DOI":"10.3390\/v14091909"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1126\/science.1256427","article-title":"Antibody landscapes after influenza virus infection or vaccination","volume":"346","author":"Fonville","year":"2014","journal-title":"Science"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Kieninger, D., Sheldon, E., Lin, W.-Y., Yu, C.-J., Bayas, J.M., Gabor, J.J., Esen, M., Roure, J.L.F., Perez, S.N., and Sanchez, C.A. (2013). Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: A phase III randomized trial in adults aged \u2265 18 years. BMC Infect. Dis., 13.","DOI":"10.1186\/1471-2334-13-343"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1111\/1348-0421.12316","article-title":"Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: A phase II trial in Japan","volume":"59","author":"Tsurudome","year":"2015","journal-title":"Microbiol. Immunol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2421096","DOI":"10.1080\/21645515.2024.2421096","article-title":"Seasonal influenza vaccines: Variability of immune responses to B lineage viruses","volume":"20","author":"Miller","year":"2024","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_38","first-page":"660","article-title":"Clinical and economic shift from trivalent to quadrivalent influenza vaccines in Europe: A systematic review","volume":"12","author":"Caini","year":"2018","journal-title":"Influenza Other Respir. Viruses"},{"key":"ref_39","first-page":"e112","article-title":"Global disappearance of influenza B\/Yamagata lineage during the COVID-19 pandemic: Implications for next-generation seasonal vaccines","volume":"24","author":"Grais","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.15585\/mmwr.mm6937a6","article-title":"Decreased influenza activity during the COVID-19 pandemic\u2014United States, Australia, Chile, and South Africa, 2020","volume":"69","author":"Olsen","year":"2020","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1038\/s41467-022-29402-5","article-title":"Human seasonal influenza under COVID-19 and the potential consequences of influenza lineage elimination","volume":"13","author":"Dhanasekaran","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_42","unstructured":"World Health Organization (2024). Recommended composition of influenza virus vaccines for use in the 2024\u20132025 northern hemisphere influenza season. Wkly. Epidemiol. Rec., 99, 125\u2013136."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.chom.2025.12.006","article-title":"Molecular basis of 60 years of antigenic evolution of human influenza A(H3N2) virus neuraminidase","volume":"34","author":"Rosu","year":"2026","journal-title":"Cell Host Microbe"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1099\/vir.0.043059-0","article-title":"Genetic evolution of the neuraminidase of influenza A(H3N2) viruses from 1968 to 2009 and its correspondence to haemagglutinin evolution","volume":"93","author":"Westgeest","year":"2012","journal-title":"J. Gen. Virol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Memoli, M.J., Shaw, P.A., Han, A., Follmann, D., Reed, S., Czajkowski, L., Bristol, T., Fargis, S., Walters, K.A., and Taubenberger, J.K. (2016). Evaluation of anti-neuraminidase antibodies as a correlate of protection against influenza in a healthy virus challenge model. mBio, 7.","DOI":"10.1128\/mBio.00417-16"},{"key":"ref_46","first-page":"102","article-title":"Meeting report: Preparedness for next-generation influenza vaccines and the role of neuraminidase-reactive antibodies","volume":"63","author":"Krammer","year":"2020","journal-title":"Biologicals"},{"key":"ref_47","first-page":"757","article-title":"In the shadow of hemagglutinin: A cryptic role for influenza virus neuraminidase antibody responses","volume":"2","author":"Wohlbold","year":"2014","journal-title":"Vaccines"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Creytens, S., Pascha, M.N., Ballegeer, M., Saelens, X., and de Haan, C.A.M. (2021). Influenza neuraminidase characteristics and potential as a vaccine target. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.786617"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e00840-19","DOI":"10.1128\/JVI.00840-19","article-title":"Extending the stalk enhances immunogenicity of the influenza virus neuraminidase","volume":"93","author":"Broecker","year":"2019","journal-title":"J. Virol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41541-019-0099-3","article-title":"A neuraminidase potency assay for quantitative assessment of neuraminidase in influenza vaccines","volume":"4","author":"Gillis","year":"2019","journal-title":"npj Vaccines"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/0264-410X(96)00061-8","article-title":"Kinetics of humoral antibody response to trivalent inactivated split influenza vaccine in subjects previously vaccinated or vaccinated for the first time","volume":"14","author":"Glathe","year":"1996","journal-title":"Vaccine"},{"key":"ref_52","first-page":"767","article-title":"The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses","volume":"70","author":"Hobson","year":"1972","journal-title":"J. Hyg."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1017\/S0022172400053158","article-title":"Immunity to attenuated influenza virus WRL 105 infection induced by heterologous, inactivated influenza A virus vaccines","volume":"79","author":"Potter","year":"1977","journal-title":"J. Hyg."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1097\/EDE.0000000000000402","article-title":"Quantifying protection against influenza virus infection measured by hemagglutination-inhibition assays in vaccine trials","volume":"27","author":"Zhao","year":"2016","journal-title":"Epidemiology"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1093\/infdis\/jit372","article-title":"Estimation of the association between antibody titers and protection against confirmed influenza virus infection in children","volume":"208","author":"Ng","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1097\/INF.0b013e3182367662","article-title":"Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children","volume":"30","author":"Black","year":"2011","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41591-022-01690-w","article-title":"Influenza virus infection history shapes antibody responses to influenza vaccination","volume":"28","author":"Auladell","year":"2022","journal-title":"Nat. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1016\/j.vaccine.2012.05.030","article-title":"Host immune response to A(H1N1)pdm09 vaccination and infection: A one-year prospective study on six cohorts of subjects","volume":"30","author":"Liu","year":"2012","journal-title":"Vaccine"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/9\/800\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T08:42:34Z","timestamp":1789116154000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/9\/800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":58,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["vaccines14090800"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14090800","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]}}}